Cart 0 Product Products (empty)
No products
To be determined Shipping
0,00 € Total
Prices are tax excluded
Product successfully added to your shopping cart
Quantity
Total
There are 0 items in your cart. There is 1 item in your cart.
Total products (tax excl.)
Total shipping (tax excl.) To be determined
Total (tax excl.)
Data sheet of NRAS polyclonal antibody
| Brand | Abnova |
| Product type | Primary antibodies |
| Reactivity | Human |
| Host species | Rabbit |
| Applications | WB-Ce,IF,WB-Tr,Flow Cyt |
More info about NRAS polyclonal antibody
| Brand: | Abnova |
| Reference: | PAB3461 |
| Product name: | NRAS polyclonal antibody |
| Product description: | Rabbit polyclonal antibody raised against synthetic peptide of NRAS. |
| Gene id: | 4893 |
| Gene name: | NRAS |
| Gene alias: | ALPS4|N-ras|NRAS1 |
| Gene description: | neuroblastoma RAS viral (v-ras) oncogene homolog |
| Immunogen: | A synthetic peptide (conjugated with KLH) corresponding to N-terminus of human NRAS. |
| Protein accession: | NP_002515;P01111 |
| Form: | Liquid |
| Recommend dilutions: | Flow Cytometry (1:10-50) Immunofluorescence (1:10-50) Western Blot (1:1000) The optimal working dilution should be determined by the end user. |
| Storage buffer: | In PBS (0.09% sodium azide) |
| Storage instruction: | Store at 4°C. For long term storage store at -20°C. Aliquot to avoid repeated freezing and thawing. |
| Note: | This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
| Product type: | Primary antibodies |
| Host species: | Rabbit |
| Antigen species / target species: | Human |
| Reactivity: | Human |
| Application image: |  |
| Application image note: | Western blot analysis of NRAS (arrow) using rabbit NRAS polyclonal antibody (Cat # PAB3461). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the NRAS gene (Lane 2) (Origene Technologies). |
| Applications: | WB-Ce,IF,WB-Tr,Flow Cyt |
| Shipping condition: | Dry Ice |
| Publications: | BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors.Banerji U, Affolter A, Judson I, Marais R, Workman P. Mol Cancer Ther. 2008 Apr;7(4):737-9. Epub 2008 Mar 28. |